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Abstract 
Purpose: To compare the tolerability and pharmacokinetic profiles of telmisartan, amlodipine, and 
hydrochlorothiazide (HCTZ) in a fixed-dose combination (FDC, test product) with a co-administered 
telmisartan/amlodipine FDC and HCTZ in a single-entity tablet (reference product) 
Methods: This was a single-dose, randomized, open-label, replicate crossover study conducted in 
healthy male Korean volunteers aged 19 – 50 years. Fasting randomized subjects received a newly 
developed test product (telmisartan/amlodipine/HCTZ, 80/10/25 mg) or two tablets of Twynsta® (40/5 
mg) and one tablet of HCTZ (25 mg) as reference products. After a washout period, each group 
replicated the exposure of the other group. 
Results: The AUClast (h•ng/mL) geometric mean was 3,194.87 and 3,273.77 for the telmisartan test and 
reference products, respectively; 329.92 and 315.13 for the amlodipine test and reference products; 
1,203.98 and 1,150.86 for the HCTZ test and reference products, respectively. The geometric mean of 
Cmax (ng/mL) was 543.04 and 497.81 for the telmisartan test and reference products, respectively; 7.74 
and 7.34 for the amlodipine test and reference products; 218.71 and 184.39 for the HCTZ test and 
reference products, respectively. For telmisartan, the 90 % CI of GMRs of AUClast (h•ng/mL) and Cmax 
(ng/mL) were 0.9414 – 1.0496 and 1.0246 – 1.2792, respectively; the coefficient of variation (CV) of 
telmisartan Cmax was 41.96 %. 
Conclusion: A formulated FDC tablet containing a telmisartan/amlodipine/HCTZ combination (80/10/25 
mg) was bioequivalent to a co-administrated commercially available telmisartan/amlodipine combination 
and HCTZ tablets at equivalent concentrations. 
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Multiple guidelines exist for the treatment of 
hypertension. The goal of hypertension treatment 
is usually to reduce blood pressure to the 
recommended range. A drug of a different class 
can be added to antihypertensive for patients 
who fail to achieve control in blood pressure [1]. 
 
Angiotensin II receptor blockers (ARBs) are 
currently the most popular class of drugs used in 
the treatment of hypertension. ARBs are 
considered good agents in terms of tolerability, 
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the convenience of a once-daily dose, and 
efficiency in lowering blood pressure. 
Telmisartan is an ARB that has high affinity to 
the AT1 receptor subtype and exhibits a long 
half-life [2-4]. Fixed-dose combinations (FDCs) 
containing telmisartan have been developed with 
the diuretic hydrochlorothiazide (HCTZ) or 
calcium channel blocker amlodipine as two active 
pharmaceutical ingredients [5-8].  
 
A telmisartan-amlodipine combination treatment 
resulted in clinically relevant blood pressure 
reduction, and was well tolerated with good 
compliance [8]. Furthermore, compared with 
monotherapy in patients with previously 
uncontrolled blood pressure, the addition of 
HCTZ to telmisartan has been associated with 
effective blood pressure reduction, as well as 
with improved hypertension goal-attainment rates 
[9]. 
 
Amlodipine is an orally active, long-lasting 
dihydropyridine calcium channel blocker (CCB) 
used to treat hypertension; the drug works by 
dilating blood vessels and is available in doses of 
5 and 10 mg. Amlodipine is also used to treat 
certain types of chest pain [10].  
 
HCTZ is a diuretic medication used to reduce the 
reabsorption of electrolytes from renal tubules, 
and is often prescribed to treat high blood 
pressure. It works by increasing urinary output 
and reducing the amount of fluid in the blood [7-
9]. 
 
Combination therapy for hypertension can be 
effective by lowering blood pressure and 
reducing cardiovascular disease, such as stroke 
[11,12]. 
 
FDCs of antihypertensive agents with different 
modes of action provide many advantages in 
treatment while maintaining lower doses of each 
component drug. Other benefits of FDCs include 
improvement of compliance, as patients are only 
required to take one dosage form, and a lower 
cost of therapy [12-14].  
 
To develop new dosage forms of FDCs, it is 
necessary to show that the FDC administered is 
therapeutically equivalent to the combined 
single-drug doses.   
 
The comparison of therapeutic equivalence can 
be conducted by evaluating the pharmacokinetic 
parameters to investigate whether the rate and 
extent of absorption of individual FDC 
components are similar to those of the co-
administered reference products. 
 
The purpose of this clinical trial was to develop 
FDCs containing the three drugs, and evaluate 
the pharmacokinetic profiles after the single-dose 
and tolerability. The results of this study were 
used to demonstrate the bioequivalence between 






Telmisartan and hydrochlorothiazide were 
obtained from Ildong Pharmaceutical Co., Ltd 
(Seoul, Korea). Amlodipine besylate was 
purchased from HanseoChem Co., Ltd. 
(Pyeongtaek, Korea). HPLC grade acetonitrile, 
methanol, water were obtained from Merck Co. 
(Darmstadt, Germany). The test FDC tablets 
were supplied from Ildong Pharmaceutical Co., 
Ltd (Seoul, Korea). The reference tablets 
telmisartan/amlodipine (Twynsta® 40/5 mg) and 
hydrochlorothiazide (Dichlozid® 25 mg) were 
supplied from Boehringer Ingelheim (Ingelheim, 





This human pharmacokinetic study was 
conducted after ethical approval (ref no. CUH-
2015-09-019-011, ChonBuk National University 
Hospital, Jeonju, Korea); all volunteers gave 
written informed consent to participate in this 
clinical trial, which was conducted in compliance 
with Korean GCP [15] and the Declaration of 
Helsinki [16]. 
 
Healthy male subjects aged between 19 to 50 
years with > 55 kg body weight and BMI (Body 
mass index) >17.5 (30.5 kg/m2) were eligible for 
participation in this clinical trial. Volunteers with 
the following history were excluded;  
cardiovascular, pulmonary, renal, 
gastrointestinal, endogeneous, or hematologic 
disease; clinical issues during the laboratory 
tests or ECG; a history of hypersensitive 
response to telmisartan, amlodipine, or HCTZ, or 
the experience of taking one of these ingredients 
within 10 days of beginning the trial; blood 





This trial was a randomized, open-label, single-
dose, replicate crossover study in healthy male 
volunteers. Forty subjects were randomized to 
two groups. For a pharmacokinetic study of an 
orally administered single dose, subjects 
received a newly developed FDC tablet 
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containing a telmisartan/amlodipine/HCTZ 
combination (80/10/25 mg, test products) or two 
tablets of Twynsta® (a telmisartan/amlodipine 
combination, 40/5 mg) and one tablet of HCTZ 
(25 mg) (reference products) over the first period. 
Over the second period, each group received the 
opposite regimen; the periods were separated by 
a 21-day washout period. After the second 
period, the test was replicated with the same 
washout period.  
 
FDC tablets of telmisartan and amlodipine were 
used instead of single-entity products as the 
reference items. Bioequivalence has been 
reported between a telmisartan/amlodipine 40/5 
mg combination (lowest strength) and a 
telmisartan/amlodipine 80/10 mg combination 
(highest strength) [17]. Because 80/10 mg 
Twynsta® tablets are not marketed in Korea, two 
tablets of 40/5 mg Twynsta® were substituted as 
the reference items. 
 
After fasting for 10 h, the subjects took the test or 
reference items with 150 mL of water. Standard 
meals were provided at 4th and 10th h after 
administration. 
 
Subjects were forbidden from eating grape fruits 
7 days before the first period through the last 
sampling in the fourth period because a number 
of calcium channel blockers can interact with the 
CYP3A4 metabolic enzyme [18]. 
 
Blood sampling  
 
For pharmacokinetic analysis, blood were 
collected before administration and at 0.25, 0.5, 
0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 
and 144 h. Seven milliliters of blood were 
collected into EDTA tubes. Only 5 mL was 
collected at 72 h and 3 mL at 96 and 144 h. 
Plasma was prepared by centrifugation of the 
blood samples at 3,000 rpm for 10 min at 4 °C. 
Samples were stored at −70 °C in polypropylene 




Analysis of each drug was performed at 
Biosuntek Laboratories Co. (Seongnam, Korea), 
which is certified by the MFDS as employing 
GLP. The methods used have been validated as 
standard operating procedures and followed 
MFDS guidelines on bioanalytical method 
validation [19]. 
 
The concentration of telmisartan, amlodipine, 
and HCTZ in plasma were analyzed by validated 
LC-MS/MS methods; the pharmacokinetic 
parameters of each drug were assessed by 
WinNonlin software (Pharsight, Sunnyvale, CA, 
USA), including AUClast (h•ng/mL), Cmax (ng/mL), 
AUCinf (h•ng/mL), Tmax (h), and t1/2 (h). 
 
Samples were stored at −70 °C until assay and 
mixed with an internal standard after thawing. 
Each component was extracted from the plasma 
using protein precipitation. The liquid 
chromatographic method used for separation 
was isocratic. 
 
In the telmisartan assay, the mobile phase 
consisted of a mixture of ACN (Acetonitrile, A) 
with 5 mM ammonium formate(B) (A:B=7:3) with 
a flow rate of 0.25 mL/min and column 
temperature of 40 °C. Detection was conducted 
with a positive electrospray ionization multiple 
reaction monitoring mode set to transmit at m/z 
515.3 → 276.2 and 441.0 → 263.2 for 
telmisartan and the internal standard, 
respectively [20,21]. 
 
In the amlodipine assay, the mobile phase 
consisted of a mixture of ACN(A) with 0.1 % 
formic acid in water(B) (1:1) with a flow rate of 
0.3 mL/min and a column temperature of 40 °C. 
Detection was conducted with a positive 
electrospray ionization multiple reaction 
monitoring mode set to transmit at m/z 409.4 → 
238.1 and 413.4 → 238.1 for amlodipine and the 
internal standard, respectively [22,23]. 
 
In the HCTZ assay, the mobile phase consisted 
of a mixture of water and methanol (15:85), with 
a flow rate of 0.3 mL/min and a column 
temperature of 40 °C. Detection was conducted 
with a negative electrospray ionization multiple 
reaction monitoring mode set to transmit at m/z 
296.0 → 269.0 and 338.2 → 78.1 for HCTZ and 
the internal standard, respectively [21,24]. 
 
As the primary parameters for establishing 
bioequivalence, AUClast and Cmax were evaluated 
for all components, and AUCinf, Tmax, t1/2, CL/F, 




Tolerability was assessed from a medical review 
of adverse events (AEs), clinical laboratory 
evaluation, vital sign measurements, physical 
examinations, and electrocardiograms. The 
subjects who had an experience of taking 
investigational products at least once were 




All participants who had an experience of taking  
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the investigational products were used in 
statistical analysis of tolerability and only those 
who finished the study were used in the analysis 
of pharmacokinetic parameters. The parameters 
were calculated as the geometric mean. 
 
Establishing bioequivalence according to MFDS 
regulations was conducted as an estimate of the 
90 % CIs of primary parameters (AUClast and 




Demographic profile of study subjects 
 
Table 1 displays the demographic characteristics 
of the 40 male subjects in this study (mean age, 
24.25 years; BMI, 23.71 kg/m2; weight, 72.94 
kg). 
 
Six subjects were excluded when they withdrew 
consent, one was excluded due to an AE 
(epigastric pain, diarrhea), and one due to 
concomitant medication. Thus, 32 subjects 




The pharmacokinetic parameters of telmisartan, 
amlodipine, and HCTZ were derived by non-
compartmental methods from plasma 
concentration time curves. The mean plasma 
concentrations of each drug were similar 
between the test and reference items; 
pharmacokinetic parameters are summarized in 
Table 2. 
 
For telmisartan, the 90 % CIs of the GMRs of 
AUClast (h•ng/mL), Cmax (ng/mL) were 0.9414 - 
1.0496, 1.0246 – 1.2792 and CV (Coefficient of 
variation) of Cmax for telmisartan was 41.96 %. 
The MFDS has been defined as a highly variable 
drug (HVD) that has a 30 % or greater intra-
subject variability of the Cmax. The bioequivalent 
acceptance range of 90% CIs of Cmax for 
telmisartan was 0.7363 – 1.3580. 
 
The 90 % CIs of the GMRs for all components 
were summarized in Table 3 satisfying the MFDS 
criteria for evaluation of bioequivalence. In 
previous pharmacokinetic studies, the variation 
of intra-subjects for telmisartan, amlodipine 
besylate and HCTZ were similar to this study 
[25,26]. 
 
Figure 2 shows the mean plasma concentration-
time profiles for telmisartan, amlodipine and 
HCTZ and the test and reference items did not 




All subjects did not show any serious or 
unexpected AEs and were considered to be well 
tolerated. Overall, 40 subjects received FDCs or 
reference products and 8 subjects experienced 
11 AEs. Six AEs were recorded in four subjects 
who were administered FDCs, and five AEs in 
four subjects who were administered reference 
products. 
 
Two AEs were moderate (upper abdominal pain, 
diarrhea), and the other cases were mild and 




In this clinical study, pharmacokinetics profiles 
and tolerability of newly developed FDCs were 
investigated in Korean male subjects and 
compared with co-administration of each 
reference item. 
 
The pharmacokinetic parameters of telmisartan, 
amlodipine, and HCTZ were similar profiles 
between the test and reference product groups in 
a replicate crossover study design. 
 
Table 1: Demographic characteristics of healthy male subjects 
 





Sex (male) N  20  20  40 
Age (years) Mean 24.10 24.40 24.25 
BMI (kg/m2) Mean 24.21 23.20 23.71 
Height (cm) Mean 176.40 173.87 175.14 
Weight (kg) Mean 75.55 70.34 72.94 
Alcohol (yes) N (%) 14 (70.0) 17 (85.0) 31 (77.5) 
Smoker (yes) N (%) 10 (50.0) 6 (30.0) 16 (40) 
Caffeine (yes) N (%) 12 (60.0) 12 (60.0) 24 (60) 
BMI = body mass index 
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Figure 1: Summary of enrolled subjects (IP, investigational products) 
 
Table 2: Comparison of the single-dose pharmacokinetic parameters of telmisartan, amlodipine, and 
hydrochlorothiazide (HCTZ) after administration of a fixed-dose combination (FDC, Test) vs. co-administration of 
reference products (reference) 
 








































































Lee et al 
Trop J Pharm Res, September 2017; 16(9): 2250  
 
Table 3: Bioequivalence of fixed-dose combination (FDC) and reference products 
 




interval of geometric 
LS mean ratio 
Coefficient of 

































































However the Tmax of telmisartan and HCTZ of 
test was slightly faster than co-administration of 
reference items, but this difference was not 
expected to have a significantly influence on 
overall absorption. Also, since the Cmax and AUC 
are major evaluation criteria of bioequivalence by 
the MFDS, we did not consider parameter of Tmax 
further. 
 
The 90 % CIs of the GMRs for AUClast and Cmax 
of all drugs were satisfactory with regard to 
bioequivalence range 0.8 to 1.25 or 0.7363 – 
1.3580. This finding from the bioavailability 
suggested that a replicate crossover study was 
well designed for newly developed FDCs 
especially with telmisartan.  
 
In the tolerability, noticeable interaction between 
telmisartan, amlodipine and HCTZ has not been 
reported in previous research. Despite co-
administration of the highest dose on the 
markets, serious and unexpected AEs were not 
different between the FDC groups and the 
reference product co-administration groups. 
 
The findings from pharmacokinetic profiles and 
tolerability indicate that these FDCs can be 
expected to exhibit similar safety and efficacy as 
commercially marketed products. The newly 
developed FDCs can replace the co-
administration of reference products expected 
improvement of compliance for patients. 
 
To clear the result of safety and efficacy 
clinically, other studies will be needed in large 




A developed FDC tablet containing 
telmisartan/amlodipine/HCTZ combination 
(80/10/25 mg) is bioequivalent to a co-admini-
stered commercially available telmisartan/ 
amlodipine combination and HCTZ tablets at 
equivalent concentrations. In this clinical study 
there were no serious or unexpected AEs and 
noticeable difference in the FDC groups and the 
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Figure 2: Mean (SD) plasma concentration-time profiles of (A) telmisartan, (B) amlodipine besylate, and (C) 
hydrochlorothiazide (HCTZ) after a single-dose administration of a fixed- dose combination (FDC) of 
telmisartan/amlodipine/HCTZ (80/10/25 mg) (Test) vs. co-administration of two tablets of telmisartan/amlodipine 
(40/5 mg) FDC and HCTZ (25 mg) 
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